we said months ago that we would end up around 3.5B total shares.....what you are saying is nothing new....all med device/biotech companies raise money and dilute
what you apparently dont get is even with 4B shares outstanding, if the stock goes to .025 thats only $100M valuation. we can go up 15x-20x from that level, which means we can have a run to a nickel prior to dilution